[1] 朱静,陈小飞.食管癌分子靶向治疗[J].东南大学学报:医学版,2011,39 (5):623-626.
[2] IWASAKI J,NIHIRA S.Anti-angiogenic therapy against gastrointestinal tract cancer[J].Jpn J Clin Oncol,2009,39(9): 543-551.
[3] 乐红琴,欧希龙,杭程,等.血管内皮生长因子165基因对人胃癌细胞侵袭性的影响[J].东南大学学报:医学版,2009,28(2):118-122.
[4] SHAH M A,JHAWER M,ILAON D H,et al.Phase Ⅱ study of modified docetaxel,cisplatin,and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma[J].J Clin Oncol,2011,29(7):868-874.
[5] van CUTSEM E,de HAAS S,KANG Y K,et al.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase Ⅲ trial[J].J Clin Oncol,2012,30(17):2119-2127.
[6] YI J H,LEE J,LEE J,et al.Randomised phase Ⅱ trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum[J].Br J Cancer,2012,106(9):1469-1474.
[7] SUN W,POWELL M,O' DWYER P J,et al.Phase Ⅱ study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203[J].J Clin Oncol,2010,28(18):2947-2951.
[8] WAINBERG Z A,ANGHEL A,DESAI A J,et al.Lapatinib,a dual EGFR and HER2 kinase inhibitor,selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo[J].Clin Cancer Res,2010,16(5):1509-1519.
[9] SCHONNEMANN K R,YILMAZ M,BJERREGAARD J K,et al.Phase Ⅱ study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer[J].Eur J Cancer,2012,48(4):510-517.
[10] SHI M,JI J,WU J,et al.Cetuximab combined with FOLFOX4 as the first-line treatment for advanced gastric cancer: report of 25 cases from a single institution[J].Hepatogastroenterology,2012,59(116): 1054-1058.
[11] MOCHLER M,MUELLER A,TRATBACH T,et al.Cetuximab with irinotecan,folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer:a prospective multi-center biomarker-oriented phase Ⅱ study[J].Ann Oncol,2011,22(6):1358-1366.
[12] DRAGOVICH T,MCCOY S,FENOGLIO-PREISER C M,et al.Phase Ⅱ trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127[J].J Clin Oncol,2006,24(30):4922-4927.
[13] YAN S Y,HU Y,FAN J G,et al.Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma[J].World J Gastroenterol,2011,17(11):1501-1506.
[14] DAI G H,SHI Y,CHEN L,et al.Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression[J].Hepatogastroenterology,2012,59(120):1026-1030.
[15] BANG Y J,van CUTSEM E,FEYEREISLOVA A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
[16] IQBAL S,GOLDMAN B,FENOGLIO-PREISER C M,et al.Southwest Oncology Group study S0413:a phase Ⅱ trial of lapatinib(GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer[J].Ann Oncol,2011,22(12):2610-2615.
[17] BEGNAMI M D,FREGNANI J H,NONOGAKI S,et al.Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication[J].Hum Pathol,2010,41(8):1120-1127.
[18] LEE K H,KIM J R.Regulation of HGF-mediated cell proliferation and invasion through NF-κB,JunB,and MMP-9 cascades in stomach cancer cells[J].Clin Exp Metastasis,2012,29(3):263-272.
[19] PARTYKA R,GONCIARZ M,JAIOWICCKI P,et al.VEGF and metalloproteinase 2(MMP 2) expression in gastric cancer tissue[J].Med Sci Monit,2012,18(4):130-134.
[20] VECCHIONE L,ORDITURA M,CIARDIELLO F,et al.Novel investigational drugs for gastric cancer[J].Expert Opin Investig Drugs,2009,18(7): 945-955.
[21] NAKATA W,HAYAKAWA Y,NAKAGAWA H,et al.Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer[J].Int J Oncol,2011,39(6):1529-1536.
[22] ZONCU R,EFEYAN A,SABATINI D M.mTOR:from growth signal integration to cancer,diabetes and ageing[J].Nat Rev Mol Cell Biol,2011,12(1):21-35.
[23] ALVARADO Y,MITA M M,VEMULAPALLI S,et al.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors[J].Target Oncol,2011,6(2):69-94.
[24] DOI T,MURO K,BOKU N,et al.Multicenter phase Ⅱ study of everolimus in patients with previously treated metastatic gastric cancer[J].J Clin Oncol,2010,28(11):1904-1910.
[25] THIEL A,MRENA J,RISTIMAKI A.Cyclooxygenase-2 and gastric cancer[J].Cancer Metastasis Rev,2011,30(3-4):387-395.
[26] AJANI J A,HECHT R J,HO L,et al.An open-label,multinational,multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated,advanced gastric or gastroesophageal cancer: the GC4 study[J].Cancer,2006,106(9): 1908-1916. |
